Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8006 in platinum-resistant ovarian cancer
NCT06545617Phase 2Withdrawn
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label trial of BAT8006 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase 2 Dose at 21 days and 9 more. Planned start Jan 2025; status: withdrawn.
02
Drugs
BAT8006
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06545617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545617.